Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02612376 · ClinicalTrials.gov registry record

Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study

A clinical trial, sponsored by University of Colorado, Denver.

Terminated
Registry status
800
Enrollment target

NCT02612376 is a clinical trial that was terminated before completion, run by University of Colorado, Denver. The registered enrollment target is 800 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02612376 was terminated before completion, sponsored by University of Colorado, Denver.

TERMINATED
Registry status
800 participants
Enrollment target

Study Summary

This study plans to establish a large bank of blood, cerebral spinal fluid (CSF), imaging, and clinical data. These data and samples will be used for future research into the causes of Alzheimer's disease (AD), Down Syndrome (DS) and other diseases that cause thinking and memory problems. This future research will also study how treatments for these diseases work. This research may help develop new treatments for some diseases of the nervous system and help understand these diseases better.

Trial Details

FieldValue
Enrollment Target 800 participants
Start Date 2016-02
Est. Completion 2025-05

Sponsor

University of Colorado, Denver

1,283 total trials

What the Registry Record Tells You About NCT02612376

The ClinicalTrials.gov registry entry for NCT02612376 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02612376 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02612376 about?

NCT02612376 is a clinical study titled "Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study". This study plans to establish a large bank of blood, cerebral spinal fluid (CSF), imaging, and clinical data. These data and samples will be used for future research into the causes of Alzheimer's disease (AD), Down Syndrome (DS) and other diseases that cause thinking and memory problems. This futur...

What is the current status of trial NCT02612376?

This trial is currently terminated. The enrollment target is 800 participants. The study started on 2016-02. Estimated completion is 2025-05.

Who is sponsoring clinical trial NCT02612376?

This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.